Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)
Octreotide and lanreotide are recommended for the treatment of secretory gastrointestinal disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea). Initiation and continued supply of octreotide/lanreotide is the responsibility of hospital or specialist services.
Octreotide and lanreotide are not licensed for this indication and there is not a large body of evidence to support this unlicensed use.
Patients should be reviewed within 4 weeks of initiation of somatostatin analogues. Continuation of treatment should only be recommended if clinicians judge that patients have derived a meaningful response from somatostatin treatment (reduced stoma output, stool volume and progression towards closure of fistulas).
Reason for decision: